New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
La Jolla Pharmaceutical Company (LJPC)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for La Jolla Pharmaceutical Company
Aggregated Option Exercises Last Year-end Values
Amendment 1995 Employee Stock Purchase Plan
Amendments Articles Incorporation Bylaws Change
Annual Meeting Proposals
Anti-takeover Devices Prevent Changes Management
Availability Additional Information
Award Types
Because Number Companies Compete Greater Resources Face Rapid
Beneficial Ownership Reporting Compliance
Blood Test Measure Binding Affinity Riquent Not Been
Board Committees Meetings Related Matters
Board Directors
Class
Class Currently Serving Until 2007 Annual Meeting
Class Currently Serving Until 2008 Annual Meeting
Class Currently Serving Until 2009 Annual Meeting
Class Currently Serving Until 2010 Annual Meeting
Code Conduct
Committees Board Directors
Common Stock Price Volatile Decline Even Business Doing
Common Stock Subject Plan
Communications Board Directors
Compensation Committee Interlocks Insider Participation
Compensation Committee Report
Compensation Discussion Analysis
Continuing Directors
Corporate Governance Guidelines
Corporate Governance Guidelines Committee Charters
Corporate Transactions
Costs Associated Exit Disposal Activities
Current Future Clinical Trials Delayed Halted
Currently Devoting Nearly Resources Development Approval Riquent Accordingly
Delivery Documents Stockholders Sharing Same Address
Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment
Director Attendance Annual Meetings
Director Compensation
Director Compensation Table 2006
Director Compensation Table 2007
Director Independence
Director Nominations
Discussions Fda Not Result Obtaining Accelerated Approval Riquent
Dividend Equivalents
Drugs Not Achieve Market Acceptance
Employee Stock Purchase Plan
Employment Agreements
Entry Material Definitive Agreement
Equity Compensation Plan Information
Even Receive Regulatory Approval Product Candidates Subject Ongoing
Executive Officers Registrant
Exercise Price
Face Environmental Liabilities Related Certain Hazardous Materials Used
Failure Achieve Maintain Effective Internal Controls Accordance 404
Federal Income Tax Consequences
Financial Statements Exhibits
Form Option Grant
Freedom Operate Business Profit Fully Sales Products Limited
Future Sales Stock Stockholders Negatively Affect Market Price
Future Stock Removed Listing Nasdaq Quotation System Not
General
Grants Additional Options
Grants Incentive Awards
Grants Initial Options
Grants Plan-based Awards Table 2006
Grants Plan-based Awards Table 2007
Held Thursday 2006
Held Thursday 2007
Held Thursday 2008
History Losses Not Become Profitable
Incorporation Reference
Independent Registered Public Accounting Firm
Independent Registered Public Accounting Firm Fees
Interest Certain Persons Matters Acted
Interruption Operation Sole Manufacturing Facility Disrupt Operations
Jolla Pharmaceutical
Jolla Pharmaceutical 1995 Employee Stock Purchase Plan
Lack Experience Marketing Products Commercial Sale
Lead Independent Director
Limited Manufacturing Capabilities Experience Result Shortages Products Clinical
Material Modifications Rights Security Holders
Miscellaneous
Need Additional Funds Support Operations
Need Sell Stock Assets Enter Collaborative Agreements Reduce
Nominees Director
Not Able Take Advantage Orphan Drug Designation Riquent
Not Earn Much Income Hope Due Possible Changes
Not Obtain Subpart Approval Riquent Raise Additional Funds
Not Pay Dividends Negatively Affect Price Stock
Obtain Regulatory Approval Riquent Validate Manufacturing Facilities Processes
Option Exercises Stock Vested 2006
Option Exercises Stock Vested 2007
Options
Order Complete Ongoing Clinical Trial Riquent Need Additional
Order Complete Ongoing Clinical Trial Riquent Need Enroll
Other Events
Other Matters Business
Other Provisions
Performance Awards
Plan
Plan Benefits
Purpose Plan
Reasons Proposal
Recent Developments
Regulation Disclosure
Regulatory Approvals Obtain Product Candidates Limited Subsequent Issues
Related Party Transactions
Report Audit Committee
Report Compensation Committee Executive
Required Design Conduct Additional Trials
Research Development Operations Depend Part Key Employees Losing
Restraint
Restricted Stock
Results Clinical Trials Not Sufficient Obtain Approval Market
Results Operations Financial Condition
Retaining Current Personnel Recruiting Additional Critical Success
Review Approval Related Party Transactions
Riquent Other Potential Products Clinical Trials Well Sale
Risk Factors
Role Executives Compensation Decisions
Rule 14a-101
Signatures
Size Market Potential Products Uncertain
Stock Appreciation Rights
Stock Payments
Stock Performance Graph
Stockholder Proposals
Success Developing Marketing Drug Candidates Depends Significantly Ability
Summary 2004 Plan
Suppliers Not Able Provide Sufficient Quantities Materials Need
Tax Accounting Implications
Technology Underlying Products Uncertain Unproven
Term Options Effect Termination
Termination Material Definitive Agreement
Top Form
Unregistered Sales Equity Securities
Vesting Exercise
Vote Required Recommendation Board
Vote Required Recommendation Board Directors
Voting
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour